Lōkahi Therapeutics

What Lōkahi Therapeutics does

Lōkahi Therapeutics is a pre-revenue biotechnology company formed in 2025 as a wholly-owned subsidiary of Apimeds Pharmaceuticals US, Inc., headquartered in La Jolla, California. The company's primary asset is LT-100 (Apitox), a purified honey bee venom biologic with Phase 3 clinical data demonstrating clinically significant pain relief and improved physical functioning in osteoarthritis patients, and an existing approval in South Korea. Lōkahi is pursuing a Type C meeting with the FDA Division of Anesthesiology, Addiction Medicine and Pain Medicine on May 4, 2026 to align on the U.S. regulatory pathway.

The company's technology stack includes the ai² (Actual Intelligence) Platform, described as a method for evaluating and advancing overlooked or distressed clinical assets by combining human clinical judgment with AI-assisted analysis. This platform is extended externally through the ai² Futures Lab academic program, which has partnerships with the University of Georgia, University of Indiana, University of San Diego, University of Idaho, University of Oregon, and University of Alabama.

Lōkahi's business model is asset-centric and licensing-driven rather than commercial. Revenue is intended to flow from regional licensing agreements, co-development structures, indication-specific collaborations, and one-time in-licensing transactions for later-stage clinical assets. The company explicitly does not sell directly to consumers or healthcare providers, and pursues B2B enterprise partnerships with pharmaceutical companies. Pricing has not been disclosed and will be determined through partnership negotiations contingent on regulatory approval. Customer concentration is structurally narrow, with the addressable base consisting of a limited set of pharmaceutical partners globally.

Name

Lōkahi Therapeutics

Legal name

Lōkahi Therapeutics Inc.

Website

https://lokahithera.com

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

1–10 employees

Short description

Lōkahi Therapeutics is a pre-revenue biotech subsidiary of Apimeds Pharmaceuticals developing LT-100 (Apitox), a purified honey bee venom biologic with Phase 3 data for osteoarthritis pain, pursuing FDA alignment and global pharmaceutical licensing partnerships.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Biologic drug development
• Pain management therapeutics
• Osteoarthritis treatment
• Pharmaceutical licensing
• Clinical asset evaluation

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Licensing & Partnerships: As a pre-revenue biotech company, Lōkahi plans to generate revenue through licensing agreements, co-development structures, and strategic partnerships for LT-100 across new markets and therapeutic areas. The company seeks regional licensing agreements, co-development structures, and indication-specific collaborations.
2. Asset Acquisition & Development: Lōkahi pursues in-licensing and strategic acquisitions of later-stage clinical assets (Phase 2 and beyond) with strong science and clean safety profiles, advancing them through development to commercialization.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Lōkahi Therapeutics is a pre-revenue biotechnology company developing LT-100 (Apitox), a purified honey bee venom biologic being studied for non-narcotic treatment of inflammation and pain, including osteoarthritis. The company pairs this lead asset with its ai² (Actual Intelligence) platform, which combines human clinical judgment and AI-supported evaluation to identify, in-license, and advance overlooked or distressed clinical assets. Revenue is planned through pharmaceutical licensing, co-development partnerships, and regional out-licensing arrangements.

Product overview

Lōkahi Therapeutics operates as a unified biotechnology platform centered on the development and advancement of LT-100 (Apitox), a novel non-narcotic therapy derived from purified honey bee venom for osteoarthritis. The company's infrastructure includes the ai² (Actual Intelligence) Platform, which combines human expertise with AI-driven evaluation to identify, acquire, and advance clinical assets, and the ai² Futures Lab™ program, which extends these capabilities through university partnerships to evaluate distressed clinical assets across clinical review, market analysis, and financial outlook stages.

Differentiator

Problem solved

Functional benefit

Brands

• ai² Futures Lab™: An innovation initiative under Lōkahi's ai² platform that partners with leading universities to give students hands-on exposure to the strategic side of biopharma, from evaluating clinical assets to understanding intellectual property, market dynamics, and go-to-market strategies.

Products and services

• LT-100 (Apitox) A novel, non-narcotic biologic derived from purified honey bee venom being studied for the treatment of inflammation and pain, including osteoarthritis. It has demonstrated clinically significant pain relief and improved physical functioning in Phase 3 trials, originally developed and approved in South Korea, with FDA Type C meeting scheduled for May 4, 2026 to discuss the U.S. regulatory pathway. Intended for pharmaceutical partners via licensing and co-development.

Quantifiable outcome

• Phase 3 trial demonstrated clinically significant pain relief and improved physical functioning
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered core.

• University of Georgia - Student Industry Fellows ProgramcoreStrategic or Co-development Partner · 1 February 2026Lōkahi Therapeutics partnered with the University of Georgia's Student Industry Fellows Program for its ai² Futures Lab program during Spring 2026. Multidisciplinary student teams work with company leadership on real-world biotech projects involving asset evaluation and strategic pathway development, bridging academic learning with industry execution.
• University of GeorgiacoreStrategic or Co-development PartnerLocated at Herty Drive, Athens, GA 30602, United States. Partner institution in the ai² Futures Lab program providing students experiential learning opportunities in biopharma strategy.
• University of IndianacoreStrategic or Co-development PartnerLocated at 107 South Indiana Avenue, Bloomington, IN 47405, United States. Partner institution in the ai² Futures Lab program offering students exposure to strategic side of biopharma.
• University of San DiegocoreStrategic or Co-development PartnerLocated at 5998 Alcala Park Way, San Diego, CA 92110, United States. Partner institution collaborating through the Knauss School of Business at University of San Diego, with Professor Jaime Alonso Gomez, Ph.D. providing academic oversight.
• University of IdahocoreStrategic or Co-development PartnerLocated at 875 Perimeter Drive, Moscow, ID 83844, United States. Partner institution in the ai² Futures Lab program expanding Lōkahi's academic partnerships nationwide.
• University of OregoncoreStrategic or Co-development PartnerLocated at 1585 East 13th Avenue, Eugene, OR 97403-1657, United States. Partner institution in the ai² Futures Lab program providing students hands-on biopharma experience.
• University of AlabamacoreStrategic or Co-development PartnerLocated at Tuscaloosa, AL 35487, United States. Partner institution with STEM Path and CREATE Path to the MBA programs. MBA students participate in ai² Futures Lab projects with mentorship from Lōkahi leadership, including Dr. Rob Morgan providing academic direction.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cara Therapeutics: Cara developed difelikefalin (Korsuva), a non-opioid kappa opioid receptor agonist for chronic pruritus and pain. Cara is a comparable small-cap, single-mechanism, non-opioid biotech that has navigated FDA approval and out-licensing deals, serving as a useful template for Lōkahi's commercialization strategy.
• Centrexion Therapeutics: Centrexion is a late-stage non-opioid pain biotech developing CNTX-6018 (resiniferatoxin) and other analgesic candidates for osteoarthritis and chronic pain. Both companies target the same unmet need and compete for partnership deals from the same pool of pharmaceutical partners.
• Latigo Biotherapeutics: Latigo is a clinical-stage biopharma developing non-opioid pain therapeutics targeting Nav1.7/Nav1.8 sodium channels. Like Lōkahi, Latigo is pursuing differentiated, non-addictive mechanisms for pain with biotech partnership and licensing as a primary go-to-market motion.
• Aptinyx: Aptinyx is developing NMDA receptor modulators (e.g., NYX-2925) for chronic pain and CNS conditions. Aptinyx represents a comparable small-cap clinical-stage pain biotech with a novel CNS mechanism and a similar licensing-driven business model.
• Wex Pharmaceuticals: Wex is developing Halneuron (tetrodotoxin), a non-opioid biologic derived from a natural toxin for cancer and chronic pain indications. Wex and Lōkahi share the same conceptual model of using purified animal toxins as non-addictive analgesic biologics, making them the closest direct peer in mechanism and positioning.

Broad incumbents

• Vertex Pharmaceuticals: Vertex received FDA approval for suzetrigine (Journavx), the first new non-opioid pain mechanism in decades, for acute pain. Vertex represents the gold-standard large-cap benchmark for the non-opioid pain category and validates the regulatory and commercial path Lōkahi is pursuing for LT-100.
• Eli Lilly: Lilly, along with Pfizer and Regeneron, has been the primary developer of anti-NGF antibodies (e.g., tanezumab) for osteoarthritis pain. Lilly is a key potential acquirer or licensor of LT-100 and represents the principal large-pharma competitive threat in the OA pain space.
• Regeneron Pharmaceuticals: Regeneron co-developed fasinumab (anti-NGF) with Teva/Mitsubishi Tanabe for osteoarthritis pain. Regeneron is a likely strategic partner or acquirer for differentiated non-opioid pain assets like LT-100 and competes in the same therapeutic space.

Others

• Apimeds Pharmaceuticals US: Apimeds is Lōkahi's parent company and the originator of the Apitox (LT-100) program. Apimeds shares the bee venom therapeutic platform and is the corporate parent from which Lōkahi was spun out, making it the most relevant enabling/ecosystem company for the asset.

Emerging players

• Tonix Pharmaceuticals: Tonix is a small-cap biopharma developing non-opioid pain and CNS candidates including TNX-102 SL for fibromyalgia. Tonix represents a comparable emerging player with a similar licensing-driven model targeting the chronic pain and CNS markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/lokahi-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lōkahi Therapeutics